Online citations, reference lists, and bibliographies.
← Back to Search

Topical Corticosteroid Compounding: Effects On Physicochemical Stability And Skin Penetration Rate.

L. Krochmal, J. Wang, B. Patel, J. Rodgers
Published 1989 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Compounding compatibility studies of four corticosteroid cream products and four commonly added chemicals are presented. Physical alteration, chemical stability, micropreservative challenge status, and in vitro skin penetration were evaluated at ambient conditions for 2 months. The study was designed to generate useful, previously unavailable information to aid dispensing pharmacists and dermatologists.
This paper references



This paper is referenced by
10.1016/J.YADR.2008.09.009
Management of childhood psoriasis.
K. Cordoro (2008)
10.1016/S0149-2918(98)80091-X
Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study.
J. Koo (1998)
10.1007/978-3-7643-7724-3_5
Topical therapy II: retinoids, immunomodulators, and others
Paru R. Chaudhari (2008)
LOS ESTEROIDES ANABOLIZANTES ANDROGÉNICOS, RIESGOS Y CONSECUENCIAS ANABOLIC ANDROGENIC STEROIDS, RISKS AND CONSEQUENCES
Rafael Ernesto Avella (2012)
10.1016/S0738-081X(01)00192-4
Antiperspirants and deodorants.
A. Benohanian (2001)
10.1586/EDM.09.32
Optimizing topical therapy for psoriasis
K. Busse (2009)
10.1016/B0-08-045044-X/00235-2
Overview of Dermatological Diseases
H. Jalian (2007)
Compounded Topical Medications for Diseases of the Skin: A Long Tradition Still Relevant Today
Matthew F. Helm (2017)
10.2217/1745509X.3.5.611
Psoriasis in the elderly
A. Dawn (2007)
10.1016/1056-8719(93)90010-C
The isolated perfused bovine udder as an in vitro model of percutaneous drug absorption. Skin viability and percutaneous absorption of dexamethasone, benzoyl peroxide, and etofenamate.
M. Kietzmann (1993)
Tratamientos tópicos de la psoriasis: actualización
J. A. M. Romero (2005)
10.1007/B138733
Psoriasis and psoriatic arthritis: An integrated approach
K. Gordon (2005)
10.1159/000131082
Activity of Different Desoximetasone Preparations Compared to Other Topical Corticosteroids in the Vasoconstriction Assay
C. Borelli (2008)
10.3109/09546639009089038
Therapeutic implications of corticosteroid formulations
W. A. Vloten (1990)
10.3109/9780849375903-3
DRUGS USED FOR SKIN DISEASES
N. Kitson (1998)
10.1097/00000446-200305000-00027
Compounded drugs. Are customized prescription drugs a salvation, snake oil, or both?
P. Coyne (2003)
10.1016/S0733-8635(05)70014-0
Extemporaneous compounding. The end of the road?
M. Ling (1998)
10.1067/MJD.2001.117046
Treatment of psoriasis. Part 1. Topical therapy and phototherapy.
M. Lebwohl (2001)
10.1177/12034754020060S304
Drug Interactions in Psoriasis: The Pros and Cons of Combining Topical Psoriasis Therapies
Carin H. Endzweig-Gribetz (2002)
10.3109/9781420088687-4
An Overview of Psoriasis
M. Menter (2008)
10.1111/j.1468-3083.2011.04113.x
Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the international psoriasis council
P. V. D. van de Kerkhof (2011)
10.2217/EBO.11.27
Current treatment options in psoriasis: topical agents
Kristine B. Zitelli (2011)
10.2165/00002512-200219110-00003
Practical Management of Psoriasis in the Elderly
G. Yosipovitch (2002)
10.1097/00129191-200607000-00013
Compounded Drugs: Are customized prescription drugs a salvation, snake oil, or both?
P. Coyne (2003)
Behandling av psoriasis - Bakgrundsdokumentation
M. Ståhle (2006)
10.1016/J.JAAD.2005.04.031
A clinician's paradigm in the treatment of psoriasis.
M. Lebwohl (2005)
10.1007/978-3-642-58308-7_7
Keratolytische bzw. proteolytische Wirkstoffe und Grundlagenbestandteile
M. Gloor (2000)
10.1046/j.1365-4362.1999.00500.x
The role of salicylic acid in the treatment of psoriasis
M. Lebwohl (1999)
10.1201/9780203912683.ch2
Topical agents in the treatment of moderate-to-severe psoriasis
Kristina Callis Duffin (2008)
10.1080/10915810500257097
Final Report of the Safety Assessment of Urea1
(2005)
10.3109/09546639809160546
A comparison of the efficacy and safety of the combination mometasone furoate 0.1 %/salicylic acid 5% ointment with each of its components in psoriasis
H. Katz (1998)
10.1007/s00011-009-0065-z
Enhanced topical delivery and ex vivo anti-inflammatory activity from a betamethasone dipropionate formulation containing fish oil
M. H. Zulfakar (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar